Special Issue

Research on Ocular and Intraocular Tumors

Message from the Guest Editors

Tumors of the eve are classified as orbital or intraocular neoplasia. Orbital diseases include lymphoma and metastasis. Primary orbital tumors are rare, such as cconjunctival melanoma, and are often difficult to treat. with high rates of recurrence and metastasis. Choroidal melanoma has the highest prevalence of all primary intraocular tumors. Primary disease control and eye preservation are achieved in most patients, because effective and complementary treatment strategies, ascertaining to local tumor control, exist. Classically, brachytherapy with iodine or ruthenium plagues, proton therapy, or radiosurgery with photons are commonly being employed. Metastatic spread, however, has remained challenging and therapeutic options remain limited, although important progress has been made with immunotherapies in recent years. The current Special Issue of *Cancers* is set to highlight novel developments in translational medicine, organpreserving therapies for intraocular tumors, and innovative strategies regarding how to most appropriately deal with metastatic disease.

Guest Editors

Dr. Lothar Krause

Department of Ophthalmology, Dessau Hospital, Brandenburg Medical School Theodor Fontane, Auenweg 38, 06847 Dessau, Germany

Dr. Ilja Frank Ciernik

Departments of Radiation Oncology, Dessau Hospital, Brandenburg Medical School Theodor Fontane, Auenweg 38, 06847 Dessau, Germany

Deadline for manuscript submissions

closed (15 August 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/118466

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

